| 特集名 | 生活習慣病と骨折危険性 | |
|---|---|---|
| 題名 | 治療薬の観点からみた生活習慣病と骨粗鬆症の関連 | |
| 発刊年月 | 2010年 01月 | |
| 著者 | 岡崎 亮 | 帝京大学ちば総合医療センター第三内科 |
| 【 要旨 】 | 生活習慣病治療薬のうち，2型糖尿病治療薬であるチアゾリジン系薬は，複数の検討において骨折リスクを上昇させる可能性が指摘されている．一方，脂質異常症治療薬であるスタチンは，基礎検討から骨折抑制効果が期待されたが，臨床検討のメタ解析からは，それほど大きな骨効果は認められていない． | |
| Theme | Lifestyle-related diseases and fracture risk | |
|---|---|---|
| Title | Osteoporosis and medical treatment for lifestyle related diseases | |
| Author | Ryo Okazaki | Third Department of Medicine, Teikyo University Chiba Medical Centere |
| [ Summary ] | Some drugs that are used to treat lifestyle related diseases have effects on bone. Thiazolidinediones, which are anti-diabetic agents, have been shown to be associated with increased risk of fractures. Statins, which lower serum cholesterol levels, were expected to be beneficial for bone based on their potent effects on bones seen in experiments. However, clinical studies have revealed that statins have little, if any, effect on bone. | |